Patents Assigned to Genentech
  • STABLE ANTI-CD79B IMMUNOCONJUGATE FORMULATIONS
    Publication number: 20240325559
    Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.
    Type: Application
    Filed: April 7, 2023
    Publication date: October 3, 2024
    Applicant: Genentech, Inc.
    Inventors: Ankit R. PATEL, Jun LIU
  • TIE2-BINDING AGENTS AND METHODS OF USE
    Publication number: 20240327528
    Abstract: The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.
    Type: Application
    Filed: March 19, 2024
    Publication date: October 3, 2024
    Applicant: Genentech, Inc.
    Inventors: Minhong Yan, Gu Zhang, Nicholas John Agard, Danielle Marie DiCara, Philip E. Hass, Julie Q. Hang, Erin L. Christensen, Robert Paul Morse, Sarah Sanowar, Vittal Shivva
  • Production of proteins in glutamine-free cell culture media
    Patent number: 12103975
    Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: October 1, 2024
    Assignee: Genentech, Inc.
    Inventors: Martin Gawlitzek, Shun Luo, Christina Teresa Bevilacqua
  • SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE
    Publication number: 20240317738
    Abstract: Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.
    Type: Application
    Filed: August 25, 2023
    Publication date: September 26, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Cheol Keun CHUNG, Jie XU, Hans IDING, Kyle CLAGG, Michael DALZIEL, Alec FETTES, Francis GOSSELIN, Ngiap-Kie LIM, Andrew MCCLORY, Haiming ZHANG, Paroma CHAKRAVARTY, Karthik NAGAPUDI, Sarah ROBINSON
  • Gene expression markers and treatment of multiple sclerosis
    Patent number: 12098426
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: September 24, 2024
    Assignee: GENENTECH, INC.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
  • Modified mammalian cells
    Patent number: 12098365
    Abstract: The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: September 24, 2024
    Assignee: GENENTECH, INC.
    Inventors: Michael Wilson Laird, Shahram Misaghi, Amy Shen, Anthony Tomlinson, Inn Huam Yuk
  • Anti-hypusine antibodies and uses thereof
    Patent number: 12099064
    Abstract: The invention provides anti-hypusine antibodies and their use in detecting and isolating polypeptides containing hypusine and/or deoxyhypusine, as well as compositions and kits comprising the anti-hypusine antibodies.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: September 24, 2024
    Assignee: GENENTECH, INC.
    Inventors: Qianting Zhai, Paul J. Carter
  • Prevention of disulfide bond reduction during recombinant production of polypeptides
    Patent number: 12098211
    Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: September 24, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20240309088
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: December 21, 2023
    Publication date: September 19, 2024
    Applicant: Genentech, Inc.
    Inventors: Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • METHODS FOR VIRAL INACTIVATION AND OTHER ADVENTITIOUS AGENTS
    Publication number: 20240309314
    Abstract: The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
    Type: Application
    Filed: November 13, 2023
    Publication date: September 19, 2024
    Applicant: Genentech, Inc.
    Inventors: Masaru Ken SHIRATORI, Robert David KISS, Hardayal PRASHAD, Raquel IVERSON, Justin BOURRET, Michael KIM, Salim CHARANIYA
  • Methods for preparing antibody drug conjugates
    Patent number: 12090211
    Abstract: The subject matter described herein is directed to methods of preparing certain antibody-drug conjugates (ADCs) wherein the antibody is linked to the drug through a linker, wherein the drug contains a heteroaryl group having a secondary nitrogen, and the linker is attached to the drug via the secondary nitrogen. The resulting conjugates are useful in treating various diseases and conditions.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: September 17, 2024
    Assignee: Genentech, Inc.
    Inventors: Thomas Pillow, Peter Dragovich
  • PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES
    Publication number: 20240301080
    Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Application
    Filed: April 26, 2024
    Publication date: September 12, 2024
    Applicant: Genentech, Inc.
    Inventors: Yung-Hsiang KAO, Michael W. LAIRD, Melody Trexler SCHMIDT, Rita L. WONG, Daniel P. HEWITT
  • BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20240300974
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
    Type: Application
    Filed: November 21, 2023
    Publication date: September 12, 2024
    Applicant: Genentech, Inc.
    Inventors: Snahel PATEL, Gregory HAMILTON, Guiling ZHAO, Huifen CHEN, Blake DANIELS, Craig STIVALA
  • AMIDES AS CBL-B INHIBITORS
    Publication number: 20240300927
    Abstract: Various amide compounds that bind Cbl-B, including those that are selective for C-Cbl, and methods of making and using the same.
    Type: Application
    Filed: February 3, 2022
    Publication date: September 12, 2024
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Araz Jakalian, Michael John Lambrecht, Robin Larouche-Gauthier, Malcolm Huestis, Man Un Ung, Xiaojing Wang, Arun Yadav, Jason Robert Zbieg, Fabio Broccatelli
  • METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A VEGF INHIBITOR FOR TREATING SOLID TUMORS
    Publication number: 20240299392
    Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.
    Type: Application
    Filed: May 14, 2024
    Publication date: September 12, 2024
    Applicant: Genentech, Inc.
    Inventors: Marie EVANGELISTA, Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN, Ting-Kun Mark LIN, Stephanie Royer JOO, Sandhya Vinayak MANDLEKAR, Stuart G. LUTZKER
  • Fused ring compounds
    Patent number: 12084429
    Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: September 10, 2024
    Assignee: Genentech, Inc.
    Inventors: Sushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
  • Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant
    Patent number: 12083129
    Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: September 10, 2024
    Assignee: Genentech, Inc.
    Inventor: Kui Lin
  • NALCN Channel Protein and Modulators Thereof
    Publication number: 20240295565
    Abstract: The present disclosure relates, inter alia, to complexes of the Na+ leak channel non-selective protein (NALCN) with FAM155A (also called FAM155; Family with sequence similarity 155 member A), UNC79 (uncoordinated 79), and UNC80 (uncoordinated 80), methods of screening for molecules that modulate the activity of the complex, and identified modulators thereof.
    Type: Application
    Filed: January 5, 2024
    Publication date: September 5, 2024
    Applicants: Genentech Inc., University of Copenhagen
    Inventors: Jian Mehr-Dean Payandeh, Stephan Alexander Pless, Han Chow Chua, Marc Kschonsak
  • SYNTHESIS OF RESTRAINED COMPLEXING AGENTS
    Publication number: 20240294464
    Abstract: Improved methods of synthesis of a restrained complexing agent are described herein. Compounds, including salts and solvates thereof, and compositions relevant to the improved methods are also described.
    Type: Application
    Filed: April 22, 2024
    Publication date: September 5, 2024
    Applicant: Genentech, Inc.
    Inventors: Nicholas WONG, Francis GOSSELIN
  • Drug delivery device
    Patent number: D1042821
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: September 17, 2024
    Assignee: Genentech, Inc.
    Inventors: Hemanth Kumar Amarchinta, Bryan Andrew Click, Adam Daniel Farchone, Geoffrey Colin Wise